Building on the momentum from the recent announcement of an £8M Series A investment, PetMedix is delighted that Fabian Kausche, Dr.med.vet., M.S. will be joining their board as non-executive chairman. A qualified veterinarian, with a doctorate in veterinary pathology, a Master of Science, and as an alumnus of the Harvard Business School; Fabian has worked his way from clinical research scientist to the top global executive teams across three of the largest global animal health companies. Having recently stepped down from that role he is now turning his experience and expertise to new opportunities, including guiding PetMedix as they grow and develop.
Dr Tom Weaver, PetMedix CEO, said:
“On behalf of the Board, it gives me great pleasure to welcome Fabian in his new role as Chairperson. Our company has great potential for disrupting the companion animal therapeutics market, therefore having Fabian on our team, with his deep understanding and experience in animal health, we fully expect to achieve our ambition to become a global leader in antibody therapy in companion animals.”
Dr Kausche said:
“PetMedix has already assembled an impressive team, obtained record-breaking Series Afunding and is making great strides in bringing breakthrough antibody-based therapeutic products to market. I am delighted to join the board of this organization supporting them on their way to becoming a global leader in in this field of the animal health industry”.
Dr Kausche’s career has spanned new product development, sales, and research and development; across both human OTC and animal health products. Throughout his career, managing hundreds of people and multi-million-dollar budgets at global pharmaceutical companies including Novartis Animal Health, Merial and lately Boehringer Ingelheim Animal Health, Fabian has always brought significant and quantifiable improvements to the pipelines and departments he oversaw.
PetMedix is built on the quality of the science that underpins it, and of the people that are carrying that science out. This innovation can now be further capitalised on through Fabian’s experience and technical skill-set. Having brought drugs to market before, and considered projects from both a commercial and a scientific standpoint, he is perfectly placed to facilitate PetMedix’s transition from an R&D stage biotech company, through to a clinical stage animal health company, and eventually one that has licensed drugs on the market that will have real impact to the health and wellbeing of animals the world over.
